Dercum’s disease, also known as adiposis dolorosa, is a disease characterized by multiple growths called lipomas. Lipomas are found under the epidermis and cause mild to severe discomfort when touched. It usually affects the trunk, upper arms, and upper legs. Dercum’s disease market report by Market Research Future (MRFR) outlines drivers, opportunities, and challenges in a comprehensive manner.
The global Dercum’s disease market is expected to touch a towering valuation by exhibiting 7.1% CAGR from 2018 to 2023 (forecast period). The emergence of cases of rare diseases can drive market demand. Ultrasound therapy and other methods of non-invasive diagnosis are bound to bolster market growth. This is backed by the large healthcare expenditure accorded by governments for the welfare of citizens. Research studies linking the disease to obesity disorders as well as patient genetic history can bode well for the market.
Clinical trials are being conducted by pharmaceutical companies and government research institutes are touted to fuel the market due to the development of new compounds or drugs. For instance, the novel compound RZL-012 without a generic or branded name has been known to target areas with lipomas and cause lipolysis. It has shown a moderate degree of success in a collaborated clinical trial conducted on women by Raziel Therapeutics and the University of Arizona.
Get sample copy @ https://www.marketresearchfuture.com/sample_request/6350
Combination therapies can prove to be a potential outlet for patients suffering from the disease. Stem cell treatments and reimbursement policies covering initial prescription drugs can prove lucrative for drug manufacturers. Partnerships with hospital chains can be another business model which can work in favor of the global Dercum’s disease market.
But low awareness of the rare disease can hamper its growth.
The global Dercum’s disease market is segmented by treatment, distribution channel, and end-user.
By treatment, it is segmented into acupuncture, surgery, electrotherapy, medication, liposuction, and others. Electrotherapy can show the way for an effective treatment for patients with the debilitating disease. Frequency rhythmic electrical modulation system (FREMS) and its subsequent success on the administration to patients can drive the segment growth till 2023.
By distribution channel, it is segmented into hospital pharmacies, retail pharmacies, and others.
By end-user, it is segmented into ambulatory surgical centers, hospitals, and others.
Europe, the Middle East & Africa (MEA), Asia Pacific (APAC), and the Americas are regions covered in the Dercum’s disease market report.
The Americas are pegged to dominate the global market due to awareness of the disease by patients with the help of online forums. The large healthcare expenditure and an established healthcare sector with sufficient methods for treatment and diagnosis can propel the regional Dercum’s disease market growth. A large number of research and development activities dedicated for discerning the cause of the disease and development of reimbursement policies can work favorably for the market.
Europe can contribute to the overall market value by offering mesotherapy, treatment for reducing abnormal shapes under the skin, to patients. The treatment involves hormonal injections, nonsteroidal anti-inflammatory drugs, and injections containing various ingredients. Large healthcare expenditure allocated for the public can augur the market demand.
The APAC region can exhibit a commendable CAGR during the forecast period due to inflow of capital for research and development, economies with a well-developed healthcare framework, and high expendable income levels of citizens. Lastly, the MEA region possesses latent potential due to the recent establishment of units dedicated for diagnosis and treatment of rare diseases.
Access the complete report @ https://www.marketresearchfuture.com/reports/dercums-disease-market-6350
Hoffman-La Roche AG, St. Jude Medical Inc., Eli Lilly and Company, AstraZeneca PLC, Amgen, Johnson & Johnson, Merck & Co., Inc., Novartis, GlaxoSmithKline Plc, Valeant Pharmaceuticals, Syneron Medical, Abbvie, Inc., Alimed, Inc., and Pfizer, Inc. are some of the noteworthy players in the global Dercum’s disease market.
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Market Research Future
+1 646 845 9312